Cancer patient blood contains cancer and non-cancer DNA. All DNA is extracted from serial cancer patient samples, sequenced in powerful NGS machines and the quantity of cell-free tumor DNA (“tcfDNA”) determined by Chronix Biomedical’s proprietary technology. The propriety technology counts the gains and losses from large sections of chromosomes present in the genome of cancer cells and summarizes the results into a copy number instability score (“CNI score”). Changes in CNI levels during therapy usually indicates a remission or progression of the tumor. The Chronix Biomedical tests have a higher accuracy in monitoring systemic cancer therapy than all traditional biomarkers. Blood Liquid Biopsies are simpler, less invasive and safer to obtain then conventional tissue biopsies.
Organ transplant patients’ blood contains the donor and the organ’s DNA. The company’s technology has enabled the development of a cost-effective and robust liquid biopsy assay with digital droplet polymerase chain reaction (“ddPCR”), which allows the earliest detection of organ transplantation rejection reactions. The amount of Graft derived DNA (“GcfDNA”) is measured in the blood. As with the lack of suitable tests to measure therapeutic efficacy in treating a cancer patient, there is also a lack of accurate biomarkers to determine if a transplanted organ is being rejected by a patient being treated with immunosuppressive drugs.